|
1.4 BIOLOGIE - TECHNOS
|
|
|
2019 Tech Speculations: Oxford Nanopore [Omics! Omics!]
|
|
|
|
|
|
Getting into the clinic is a priority for any company selling biological analysis capabilities. Each time I go to a nanopore meeting, it seems another good application surfaces -- pre-implantation cytogenetics that avoids freezing embryos, rapid diagnosis of infections to match antibiotics to bugs*, rapid diagnosis of cancer fusions to match tumors to drugs. Some of these not only have the speed advantage, but also long reads are inherently better than short.
|
|
|
|
|
|
|
2. ETIOLOGIE
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
Targeting Brachyury Transcription Factor Addiction in Chordoma [ESMO]
|
|
|
|
|
|
Identification of therapeutic targets in chordoma has been challenging so far, due to the infrequent occurrence of clinically actionable somatic mutations. The latest study revealed that the developmental transcription factor T (brachyury; TBXT) is the top selectively essential gene in chordoma.
|
|
|
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
FDA, EMA recommend against starting patients on Lilly's Lartruvo [Biopharma Dive]
|
|
|
|
|
|
Both the EMA and FDA had granted Lartruvo early approval based on Phase 2 results that indicated the medicine could prolong overall survival and progression-free survival when given in combination with the existing cancer treatment doxorubicin. Yet data from the larger Phase 3 trial showed no significant survival benefit when compared with doxorubicin alone.
|
|
|
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
6.10 POLITIQUES
|
|
|
|
|
|
|
6.11 PATIENTS
|
|
|
Cancer cliches to avoid: I'm not 'brave' [BBC News]
|
|
|
|
|
|
Calling a person's cancer diagnosis a "war" or a "battle" and saying they had "lost their battle" or "lost their fight" when they died, were other unpopular descriptions, according to the poll carried out by YouGov.
|
|
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|
Julia Lab joins team to speed up drug approval process [MIT]
|
|
|
|
|
|
The team aims to leverage real-world evidence, observational data that are generated during routine clinical practice, and patient health care databases to augment label claims and/or support new drug applications with leading-edge software and algorithms and a depth of regulatory and clinical experience.
|
|
|
|
|
|
|